In patients with EGFR-mutant NSCLC, dose reduction (25 mg/day) of erlotinib can reduce the toxicity while maintaining efficacy.[12] In contrast, a prospective phase II trial involving low-dose erlotinib in patients with EGFR-mutant NSCLC revealed that dose reduction (50 mg/day) is not recommended because of reduced efficacy.[13] Intermittent erlotinib administration on alternate days successfully maintained efficacy while reducing toxicity.[14] Here, disease control was possible by RC of platinum doublets for approximately 6 cycles after the 6-month treatment holiday. Here, EGFR is linked to non-small cell lung carcinoma.